Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Zentalis Pharmaceuticals has received a consensus rating of "Hold" from six analysts, with one sell rating, three hold ratings, one buy rating, and one strong buy rating.
• The company's average one-year price target is $5.84, but shares opened at only $1.49 on Monday, indicating a significant gap.
• Institutional investors have increased their stakes in Zentalis, with Millennium Management boosting its position by 220.6% in the first quarter.

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) have been given a consensus rating of "Hold" by the six analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $5.84.

ZNTL has been the subject of a number of research reports. Wells Fargo & Company dropped their target price on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an "equal weight" rating for the company in a report on Thursday, August 7th. HC Wainwright raised shares of Zentalis Pharmaceuticals to a "strong-buy" rating in a report on Thursday, August 7th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Zentalis Pharmaceuticals in a report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Zentalis Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Saturday, August 9th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC boosted its position in shares of Zentalis Pharmaceuticals by 220.6% during the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company's stock valued at $4,881,000 after acquiring an additional 2,111,951 shares during the last quarter. Acadian Asset Management LLC boosted its position in shares of Zentalis Pharmaceuticals by 4.7% during the 2nd quarter. Acadian Asset Management LLC now owns 2,799,020 shares of the company's stock valued at $3,241,000 after acquiring an additional 124,985 shares during the last quarter. Almitas Capital LLC boosted its position in shares of Zentalis Pharmaceuticals by 5.2% during the 1st quarter. Almitas Capital LLC now owns 1,710,921 shares of the company's stock valued at $2,720,000 after acquiring an additional 84,025 shares during the last quarter. Tybourne Capital Management HK Ltd. boosted its position in shares of Zentalis Pharmaceuticals by 53.7% during the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 1,478,152 shares of the company's stock valued at $1,715,000 after acquiring an additional 516,666 shares during the last quarter. Finally, Balyasny Asset Management L.P. acquired a new position in Zentalis Pharmaceuticals in the second quarter valued at about $1,126,000.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ ZNTL opened at $1.49 on Monday. The firm has a market cap of $107.49 million, a PE ratio of -0.66 and a beta of 1.77. The firm has a fifty day moving average of $1.60 and a 200 day moving average of $1.42. Zentalis Pharmaceuticals has a one year low of $1.01 and a one year high of $4.44.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.19. On average, equities analysts predict that Zentalis Pharmaceuticals will post -2.42 EPS for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.